Discrimination values of simplified IPSSWM at initiation of first-line treatment for subsequent survival and for survival after different yearly landmark time points during the first 6 years of follow-up
| Landmark time point, mo . | Number at risk . | Number of subsequent deaths . | Harrell C (95% CI) . | Somers Dxy (95% CI) . |
|---|---|---|---|---|
| 0 | 104 | 61 | 0.621 (0.557-0.685) | 0.243 (0.116-0.370) |
| 12 | 88 | 50 | 0.594 (0.520-0.668) | 0.180 (0.041-0.335) |
| 24 | 73 | 41 | 0.540 (0.460-0.621) | 0.081 (−0.081-0.244) |
| 36 | 67 | 37 | 0.555 (0.468-0.642) | 0.111 (−0.06-0.285) |
| 48 | 61 | 33 | 0.544 (0.453-0.635) | 0.089 (−0.093-0.271) |
| 60 | 55 | 29 | 0.519 (0.428-0.610) | 0.038 (−0.144-0.220) |
| 72 | 45 | 24 | 0.543 (0.434-0.651) | 0.086 (−0.131-0.303) |
| Landmark time point, mo . | Number at risk . | Number of subsequent deaths . | Harrell C (95% CI) . | Somers Dxy (95% CI) . |
|---|---|---|---|---|
| 0 | 104 | 61 | 0.621 (0.557-0.685) | 0.243 (0.116-0.370) |
| 12 | 88 | 50 | 0.594 (0.520-0.668) | 0.180 (0.041-0.335) |
| 24 | 73 | 41 | 0.540 (0.460-0.621) | 0.081 (−0.081-0.244) |
| 36 | 67 | 37 | 0.555 (0.468-0.642) | 0.111 (−0.06-0.285) |
| 48 | 61 | 33 | 0.544 (0.453-0.635) | 0.089 (−0.093-0.271) |
| 60 | 55 | 29 | 0.519 (0.428-0.610) | 0.038 (−0.144-0.220) |
| 72 | 45 | 24 | 0.543 (0.434-0.651) | 0.086 (−0.131-0.303) |
IPSSWM at initiation of first-line treatment was available in 104 patients.